Key terms

About REGN

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
     
52-week range
     
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date

Key terms

Smart score

Latest REGN news

Mar 26 8:45am ET Truist Financial Remains a Buy on Regeneron (REGN) Mar 26 4:51am ET Analysts Offer Insights on Healthcare Companies: United Therapeutics (UTHR), Regeneron (REGN) and Intuitive Surgical (ISRG) Mar 25 12:40pm ET Analysts Offer Insights on Healthcare Companies: Regeneron (REGN) and Alphatec Holdings (ATEC) Mar 25 12:31pm ET Analysts Offer Insights on Healthcare Companies: Alphatec Holdings (ATEC) and Regeneron (REGN) Mar 25 7:02am ET Regeneron receives CRL from FDA on odronextamab BLA Mar 19 1:36am ET Buy Rating Affirmed for Regeneron on Eylea HD Success and Innovative Obesity Program Mar 13 7:09am ET Regeneron price target raised to $1,115 from $1,104 at Morgan Stanley Mar 13 5:01am ET Analysts’ Top Healthcare Picks: Cooper Co (COO), Regeneron (REGN) Mar 12 9:51am ET Oracle, Dollar General upgraded: Wall Street’s top analyst calls Mar 11 4:11pm ET Regeneron initiated with an Outperform at Bernstein Mar 11 7:37am ET Regeneron says FDA has extended approval of Praluent Mar 08 7:30am ET Analysts Are Bullish on Top Healthcare Stocks: Amgen (AMGN), Regeneron (REGN) Mar 08 7:06am ET Regeneron published one-year results from PULSAR, PHOTON, met primary endpoint Mar 05 7:28am ET 2seventy bio: Close of asset sale to Regeneron seen in 1H24 Feb 27 8:34am ET Regeneron price target raised to $1,184 from $1,096 at RBC Capital Feb 27 7:51am ET Analysts Are Bullish on Top Healthcare Stocks: ANI Pharmaceuticals (ANIP), Boston Scientific (BSX) Feb 27 7:47am ET Truist Financial Gives a Buy Rating to Regeneron (REGN) Feb 27 12:30am ET Analysts Offer Insights on Healthcare Companies: Korro Bio (KRRO), Relay Therapeutics (RLAY) and Regeneron (REGN) Feb 23 7:25am ET Buy Rating Affirmed: Regeneron’s Strategic Growth in Obesity Metabolic Space Feb 23 5:16am ET Regeneron, Sanofi announce FDA acceptance for priority review of Dupixent sBLA Feb 21 7:35am ET Regeneron sees FY24 adjusted EPS $1.42-$1.49, consensus $1.77 Feb 21 7:18am ET Regeneron announces U.S. FDA accepted priority review for BLA for linvoseltamab Feb 16 5:26am ET Regeneron, Sanofi announce MHLW in Japan approves Dupixent Feb 15 9:44am ET Regeneron price target raised to $1,060 from $920 at Argus Feb 15 3:20am ET Analysts Offer Insights on Healthcare Companies: Health Catalyst (HCAT), Regeneron (REGN) and Merck & Company (MRK) Feb 09 4:14pm ET Regeneron exec LaRosa sells 1,000 common shares Feb 07 8:25am ET Buy Rating Affirmed for Regeneron on Strong Drug Pipeline and Market Growth Potential Feb 06 7:50am ET Analysts’ Top Healthcare Picks: Intuitive Surgical (ISRG), Vertex Pharmaceuticals (VRTX) Feb 06 7:25am ET Strong Buy: Regeneron’s Growth Potential and Strategic R&D Investments Feb 06 1:00am ET Regeneron Pharmaceuticals Is Worried About This – Should You Be Worried Too? Feb 05 10:11am ET Regeneron price target raised to $1,135 from $1,045 at Truist

REGN Financials

1-year income & revenue

Key terms

REGN Forecasts

analyst rating

  • buy
  • hold
  • sell

We're sorry, but this
information is
temporarily unavailable.

1-year stock price forecast

REGN Competitors

$ Market cap P/E ratio $ Price 1d change 52-week range

Key terms